Skip to main content
HR 2831 117th Congress House Health Drug safety, medical device, and laboratory regulation Marketing and advertising

Prompt Approval of Safe Generic Drugs Act

Introduced: April 26, 2021 Introduced by: Barragán, Nanette Diaz Democratic · California See on congress.gov
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 27, 2021
Referred to the Subcommittee on Health.
Apr 26, 2021
Referred to the House Committee on Energy and Commerce.
Apr 26, 2021
Introduced in House
 Plain-English summary Congressional Research Service

Prompt Approval of Safe Generic Drugs Act

This bill authorizes the Food and Drug Administration (FDA) to approve certain applications to market a drug even if the drug's labeling lacks certain safety information.

Specifically, an abbreviated application for approval of a generic drug shall not be ineligible for approval solely because the drug's labeling omits safety information that is protected under another drug's exclusivity protections. Similarly, a drug that is approved under this bill shall not be considered mislabeled for lacking such safety information.

Generally, an abbreviated application, for the purposes of this bill, is one that (1) uses required information from studies not conducted by the applicant; or (2) seeks approval of a drug that is, for drug approval purposes, a duplicate of an already-approved drug.

For any drug approved under this bill, the FDA shall require the drug's labeling to include any safety information that is necessary to assure safe use.

What's happening now April 27, 2021

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2